Identification, Characterization and Initial Hit-to-Lead Optimization of a Series of 4-Arylamino-3-Pyridinecarbonitrile as Protein Kinase C theta (PKCθ) Inhibitors
作者:Derek C. Cole、Magda Asselin、Agnes Brennan、Robert Czerwinski、John W. Ellingboe、Lori Fitz、Rita Greco、Xinyi Huang、Diane Joseph-McCarthy、Michael F. Kelly、Matthew Kirisits、Julie Lee、Yuanhong Li、Paul Morgan、Joseph R. Stock、Désirée H. H. Tsao、Allan Wissner、Xiaoke Yang、Divya Chaudhary
DOI:10.1021/jm800214a
日期:2008.10.9
The protein kinase C (PKC) family of serine/threonine kinases is implicated in a wide variety of cellular processes. The PKC theta (PKCO) isoform is involved in TCR signal transduction and T cell activation and regulates T cell mediated diseases, including lung inflammation and airway hyperresponsiveness. Thus inhibition of PKCO enzyme activity by a small molecule represents an attractive strategy for the treatment of asthma. A PKCO high-throughput screening (HTS) campaign led to the identification of 4-(3-bromophenylamino)-5-(3,4-dimethoxyphenyl)-3-pyridinecarbonitrile 4a, a low mu M ATP competitive PKC theta inhibitor. Structure based hit-to-lead optimization led to the identification of 5-(3,4-dimethoxyphenyl)-4(1H-indol-5-ylamino)-3-pyridinecarbonitrile 4p, a 70 nM PKC theta inhibitor. Compound 4p was selective for inhibition of novel PKC isoforms over a panel of 21 serine/threonine, tyrosine, and phosphoinositol kinases, in addition to the conventional and atypical PKCs, PKC beta, and PKC zeta, respectively. Compound 4p also inhibited IL-2 production in antiCD3/anti-CD28 activated T cells enriched from splenocytes.